{"protocolSection": {"identificationModule": {"nctId": "NCT00400985", "orgStudyIdInfo": {"id": "SENSE-HF, V.1, Dec.8, 2004"}, "organization": {"fullName": "Medtronic Bakken Research Center", "class": "INDUSTRY"}, "briefTitle": "Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure", "officialTitle": "Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure", "acronym": "SENSE-HF"}, "statusModule": {"statusVerifiedDate": "2018-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-01"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-13", "studyFirstSubmitQcDate": "2006-11-16", "studyFirstPostDateStruct": {"date": "2006-11-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-02-14", "resultsFirstSubmitQcDate": "2018-01-09", "resultsFirstPostDateStruct": {"date": "2018-10-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-01-09", "lastUpdatePostDateStruct": {"date": "2018-10-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Medtronic Bakken Research Center", "class": "INDUSTRY"}, "collaborators": [{"name": "Medtronic", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The SENSE-HF study is a prospective, observational, international multi-center study prospectively evaluating the sensitivity and positive predictive value of the OptiVol Fluid Trends data in predicting Heart Failure related hospitalizations and health care utilizations associated with signs and/or symptoms of pulmonary congestion, and to define OptiVol clinical guidelines for subject therapy management.", "detailedDescription": "The SENSE-HF study prospectively evaluates the OptiVol feature in the prediction of Heart Failure related events associated with signs and symptoms of pulmonary congestion and in the subject HF therapy management.\n\nThe OptiVol feature is based on the measurement of daily intrathoracic impedance values, measurements that can be used to track changes in the subject's thoracic fluid status over time. An Alert warns the patient whenever a programmable threshold has been reached.\n\nThe study is divided into three phases.\n\nThe first phase is double-blinded and designed to determine the sensitivity and positive predictive value of the OptiVol Fluid Trends data for the detection of Heart Failure related hospitalizations with signs and/or symptoms of pulmonary congestion.\n\nIn the second phase of the study, the Alert is turned ON and the positive predictive value of the first OptiVol Patient Alert for the development of signs and/or symptoms of pulmonary congestion will be evaluated.\n\nThe third phase of the study allows for remote subject therapy management using the OptiVol Patient Alert. The patient management strategy is then based on the experience gained in the second study phase Physician actions taken in the occurrence of a Patient Alert will be summarized."}, "conditionsModule": {"conditions": ["Heart Failure, Congestive"], "keywords": ["Heart Failure, Congestive", "Diagnostic", "Ambulatory Monitoring", "Intrathoracic Impedance"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 501, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Implantable Device diagnostics", "type": "OTHER", "description": "All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off", "interventionNames": ["Device: Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool."]}], "interventions": [{"type": "DEVICE", "name": "Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.", "description": "SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.", "armGroupLabels": ["Implantable Device diagnostics"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion.", "timeFrame": "34 days post device implant to 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Successfully implanted InSync Sentry device (\\< 34 days post implant or pocket revision)in the pectoral region;\n* At least one HF-related hospitalization that required administration of IV medication (inotropes, nitrates, diuretics) within the last 12 months\n* The Subject has a market released, transvenous, high voltage Right Ventricular lead\n* The Subject is able to detect a Patient Alert signal\n\nExclusion Criteria:\n\n* \\<18 years of age (or under a minimum age required by local law)\n* Moderate to severe Chronic Obstructive Pulmonary Disease (COPD)\n* Post heart transplant or awaiting heart transplantation\n* Primary pulmonary hypertension\n* Renal insufficiency requiring dialysis\n\nAmendment to the inclusion criteria (Jul 06):\n\n* Inclusion of patients with Concerto/Virtuoso devices.\n* At least one HF-related hospitalization that required administration of IV (or uptitration of the oral medication)(inotropes, nitrates, diuretics)within the last 12 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Viviane Conraads, Professor", "affiliation": "UZA, Antwerpen, Belgium", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Martin Cowie, Professor", "affiliation": "Royal Brompton Hospital, London, UK", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UZA", "city": "Antwerpen", "country": "Belgium", "geoPoint": {"lat": 51.21989, "lon": 4.40346}}, {"facility": "Royal Brompton", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"references": [{"pmid": "16061743", "type": "BACKGROUND", "citation": "Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, Christensen J, Stadler RW, Lau CP. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005 Aug 9;112(6):841-8. doi: 10.1161/CIRCULATIONAHA.104.492207. Epub 2005 Aug 1."}, {"pmid": "21362703", "type": "RESULT", "citation": "Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, Cowie MR. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J. 2011 Sep;32(18):2266-73. doi: 10.1093/eurheartj/ehr050. Epub 2011 Feb 28."}, {"pmid": "24519908", "type": "DERIVED", "citation": "Conraads VM, Spruit MA, Braunschweig F, Cowie MR, Tavazzi L, Borggrefe M, Hill MR, Jacobs S, Gerritse B, van Veldhuisen DJ. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure. Circ Heart Fail. 2014 Mar 1;7(2):279-87. doi: 10.1161/CIRCHEARTFAILURE.113.000883. Epub 2014 Feb 11."}], "seeAlsoLinks": [{"label": "Public website", "url": "http://www.medtronic.com/"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "501 patients from 41 medical clinics in 13 countries were enrolled between March 4, 2005 and September 9, 2008.", "groups": [{"id": "FG000", "title": "All Patients", "description": "All study participants received the same treatment"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "501"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "449"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "52"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "system modification", "reasons": [{"groupId": "FG000", "numSubjects": "8"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "30"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "9"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Group 1"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "501"}]}], "measures": [{"title": "Cronic Heart Failure (CHF) patients with a Cardiac Resynchronization Therapy device system", "description": "Patients with New York Heart Association (NYHA) functional class II-III and severely reduced left ventricular ejection fraction and at least one Heart Failure (HF)-related hospitalisation that required an increase of medication (inotropes, nitrates, diuretics) within the last 12 months were eligible for inclusion. Subject enrolment occurred after successful device implantation (implantable cardioverter-defibrillator (ICD), or a combination of implantable cardiac resynchronization with ICD (CRT-D) and before 34 days post-implant (at time when OptiVol Fluid Trend Data become available).", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "501"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "65", "spread": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "79"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "422"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Belgium", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "70"}]}]}, {"title": "Italy", "categories": [{"measurements": [{"groupId": "BG000", "value": "115"}]}]}, {"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "58"}]}]}, {"title": "Greece", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}]}]}, {"title": "Israel", "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}]}]}, {"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}]}]}, {"title": "Slovakia", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}, {"title": "Denmark", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}]}]}, {"title": "Czech Republic", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}]}]}, {"title": "China", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}, {"title": "Device therapy", "paramType": "NUMBER", "unitOfMeasure": "units", "classes": [{"title": "CRT-D", "categories": [{"measurements": [{"groupId": "BG000", "value": "393"}]}]}, {"title": "ICD", "categories": [{"measurements": [{"groupId": "BG000", "value": "108"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "hospitalization", "timeFrame": "34 days post device implant to 6 months", "groups": [{"id": "OG000", "title": "All Patients", "description": "All patients received the same treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "501"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.9", "eventGroups": [{"id": "EG000", "title": "Group 1", "seriousNumAffected": 42, "seriousNumAtRisk": 501, "otherNumAffected": 52, "otherNumAtRisk": 501}], "seriousEvents": [{"term": "HF related hospitalization", "organSystem": "Cardiac disorders", "stats": [{"groupId": "EG000", "numEvents": 58, "numAffected": 42, "numAtRisk": 501}]}], "otherEvents": [{"term": "Heart Failure decompensation", "organSystem": "Cardiac disorders", "stats": [{"groupId": "EG000", "numEvents": 104, "numAffected": 52, "numAtRisk": 501}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director CRDM", "organization": "Medtronic BRC, The Netherlands, Maastricht", "phone": "+31 43 3566", "phoneExt": "566"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}